The Medicines and Healthcare products Regulatory Agency (MHRA) has today announced an urgent product recall for Emerade 300mcg. The statement follows reports of difficulty in activating the pens, meaning the dose of adrenaline may not be delivered when needed by a patient for a severe, acute allergic reaction (anaphylaxis).

Patients who carry the pens are being asked to contact their doctor to arrange an alternative prescription for a different brand of pens and should ensure they have two replacement pens to carry with them, before returning the Emerade 300mcg pens to a pharmacy for sale disposal. This applies to pens due to expire as well as those which are still in date.

For more information please visit the page.